Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.
about
Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasionHuman cytomegalovirus resistance to antiviral drugsAntiviral drugs for viruses other than human immunodeficiency virusHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance: mechanisms and clinical implicationsSusceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovirInhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94Antiviral drug resistance of human cytomegalovirus.Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis.Optimal management of cytomegalovirus retinitis in patients with AIDS.Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replicationAmino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agentsComparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Photodynamic inactivation of mammalian viruses and bacteriophages.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingLimitations of cytomegalovirus testing.
P2860
Q24339602-A765E715-C7D0-48E7-8A05-A648E444A3D5Q24556634-6387E9DC-83A9-4C31-B6CA-B3F4341D6398Q24635330-7C5E0A3F-7887-4C24-BD72-83A0DD4CEF8EQ28069489-28FB5EBE-2035-4227-876B-AD4A87986B49Q28282376-57E2B4A8-77C9-4652-BC2D-E076D387ABC7Q28353356-645B2361-C5C3-4E05-9A51-7E3F98768341Q28362995-A99386BB-409A-4BCA-9EF1-D977494ADE45Q30430427-ADC3941B-1B7C-4081-B8EC-88E9809528DAQ33625721-178F8DAB-953E-4712-B581-B00F5BAB72CBQ33782295-66029FC2-0D3D-42FD-BFA2-616312ED0E1DQ33819834-AC418207-9A05-4123-9086-E6C9E6E3E9B6Q34073558-A0F12E4B-6537-45C7-BEB2-6048767E2310Q34107597-28166B4C-7F1B-4767-B646-8E3F594DC180Q34111115-3E49277F-4039-4C45-9364-87330A74E39BQ34468784-FF6C4441-4317-4BC6-84F9-06F552156533Q34590916-16CA60E5-49A1-4A65-9E01-FA5A86FCAA81Q34670354-81C1A451-3506-4727-931F-F3B72E75550FQ35557331-7E5E908A-3493-49D8-A7C6-B996F40C1D6FQ36126046-809D2367-90E9-4864-98A5-CBCE6F99DAA3Q37180338-773FEB10-9C44-4300-A1F6-8E6CE66C2538Q39652845-43254310-E32D-4B4D-8598-EFE6901DE8E6Q42728795-811B1A48-068B-41E1-8666-4F457E06A61A
P2860
Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@ast
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@en
type
label
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@ast
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@en
prefLabel
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@ast
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@en
P2093
P2860
P1476
Incidence of foscarnet resista ...... Viral Resistance Study Group.
@en
P2093
P2860
P304
P407
P577
1998-09-01T00:00:00Z